Telomir Pharmaceuticals (NASDAQ: TELO) announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that Telomir-Zn, the company's lead small-molecule therapeutic, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson's disease model. The study showed that Telomir-Zn reduced oxidative stress, lowered hepatic copper burden, and improved liver function markers, supporting its biological activity in Wilson's disease.
Wilson's disease is a genetic disorder characterized by copper accumulation in the body, primarily affecting the liver and brain. Current treatments include chelation therapy and zinc acetate, but they often come with side effects and limited efficacy. The new findings suggest that Telomir-Zn could offer a novel approach by modulating intracellular metal homeostasis and redox balance. According to the press release, the results expand the company's scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company's lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. For more information, visit the company's newsroom at https://ibn.fm/TELO.
The full press release is available at https://ibn.fm/fOSNo. Telomir Pharmaceuticals trades on the Nasdaq Capital Market under the ticker symbol TELO.
